Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.

Autores de IIS La Fe

• Jaime Sanz Caballer

  Autor

• Juan Bautista Montoro Gómez

  Autor

• Jose Ignacio Lorenzo Herrero

  Autor

• Pau Montesinos Fernández

  Autor

• Aitana Balaguer Roselló

  Autor

• Manuel Nuno Direito De Morais Guerreiro

  Autor

• Carlos Carretero Marquez

  Autor

• Guillermo Sanz Santillana

  Autor

• Miguel Ángel Sanz Alonso

  Autor

• José Luis Piñana Sánchez

  Autor

Participantes ajenos a IIS La Fe

• Solano C
• Valcárcel D
• Sampol A
• Ferrá C
• Parody R
• Ortí G
• Hernández-Boluda JC

Grupos

• Hematología y Hemoterapia

Abstract

In this prospective randomized study, we compared the outcomes of single-unit umbilical cord blood transplantation (UCBT) and unmanipulated haploidentical stem cell transplantation (haplo-SCT) with post-transplantation cyclophosphamide (PTCy) in adults with hematologic malignancies. All patients received a myeloablative conditioning (MAC) regimen consisting of thiotepa, busulfan, and fludarabine, with antithymocyte globulin (ATG) added for UCBT recipients. Nineteen patients were randomized to UCBT and the other 26 to haplo-HSCT. Four patients (15%) allocated to the haplo-HSCT arm lacked a suitable donor and were crossed over to the UCBT arm. Finally, 23 underwent UCBT and 22 underwent haplo-HSCT. The cumulative incidence of neutrophil recovery was 87% at a median of 19 days (range, 13 to 24 days) in the UCBT arm versus 100% at a median of 17 days (range, 13 to 25 days) in the haplo-SCT arm (P = .04). Platelet recovery was 70% at a median of 40 days (range, 18 to 129 days) in the UCBT arm versus 86% at a median of 24 days (range, 12 to 127 days) in the haplo-HCT arm (P = .02). Rates of acute graft-versus-host disease (GVHD) grade II-IV or grade III-IV, overall chronic GVHD, and extensive chronic GVHD in the UCBT and Haplo-SCT arms were 43% versus 36% (P = .8), 9% versus 9% (P = 1), 66% versus 43% (P = .04), and 41% versus 23% (P = .2), respectively. Two-year nonrelapse mortality and relapse in the 2 arms were 52% versus 23% (P = .06) and 17% versus 23% (P = .5), respectively. Two-year disease-free survival, overall survival, and GVHD/relapse-free survival in the 2 arms were 30% versus 54% (P = .2), 35% versus 59% (P = .1), and 17% versus 40% (P = .04), respectively. Our data show that in the context of an MAC regimen, haplo-SCT with PTCy provides improved outcomes compared with ATG-containing single-unit UCBT.

Keywords

• Allogeneic stem cell transplantation clinical trial, Alternative donor transplantation, Haploidentical transplantation, Hematologic malignancy, Umbilical cord blood transplantation